Skip to main content

Table 5 Economic impact (mean total cost) of comorbidities, divided by the number of comorbidities

From: Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice

 

HIV+ mono-infected patients

HIV/HCV co-infected patients

Delta between HIV/HCV and HIV+ patients [%]

p-value between HIV/HCV and HIV+ patients

No comorbidity

€ 8,272.18

€ 12,897.43

€ 10,382.67a

35.86%

25.51%a

< 0.001

< 0.001a

One comorbidity

€ 9,566.95

€ 17,426.32

€ 11,159.68a

82.15%

14.27%a

< 0.001

0.001a

Two comorbidities

€ 11,423.22

€ 18,348.50

€ 11,896.95a

37.74%

3.98%a

0.018

> 0.050a

Three or more comorbidities

€ 12,532.49

€ 12,755.15

€ 12,228.53a

1.75%

− 2.49%a

> 0.050

> 0.050a

One way ANOVA

0.095

0.0554

  
  1. aAverage cost without considering costs incurred for HCV therapy